ReviewFrontiers in oncology2018

Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy.

Sebastian Kobold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.